On Wednesday, H.C. Wainwright analyst Emily Bodnar raised the stock rating for Arcus Biosciences (NYSE:RCUS) from Neutral to Buy, setting a price target of $24.00. The upgrade comes as the stock ...
--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback